#ESC22: CinCor CMO’s 17-year journey in bringing a new hypertension drug to market continues
BARCELONA — Sixteen years ago, Mason Freeman was “very disappointed.” A first-in-human study of an aldosterone synthase inhibitor, or ASI, had done what it was supposed to do: block aldosterone production. But it also blocked cortisol.
So, his managers at Novartis scrapped the program that the decades-long Harvard/Mass General physician and a French professor had drummed up just a year earlier.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.